Idiopag 25mg

Tablet
Eltrombopag Olamine
Healthcare Pharmaceuticals

Other Strength:
- Idiopag 50mg

Alternative:
- Eltropag 25mg



Idiopag
Description
Idiopag® tablets contain eltrombopag olamine, a small molecule thrombopoietin (TPO) receptor agonist for oral administration. Eltrombopag interacts with the transmembrane domain of the TPO receptor (also known as cMpl) leading to increased platelet production

Indications
Eltrombopag Olamine is a thrombopoietin receptor agonist indicated for the treatment of:
 Thrombocytopenia in adult and pediatric patients (1 year and older) with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.
 Thrombocytopenia in patients with Chronic Hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag should be used only in patients with Chronic Hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy.
 Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.

Supply
Idiopag® 25 mg: Each commercial box contains 1x7’s tablets in Alu-Alu blister pack.
Idiopag® 50 mg: Each commercial box contains 1x7’s tablets in Alu-Alu blister pack.

এই পাতাটি ৪৭৪ বার দেখা হয়েছে